Glofitamab for relapsed or refractory B-cell lymphoma
Dr. Michael Dickinson
Glofitamab is a T-cell-engaging bispecific antibody possesing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. A multinational phase 1 study found manageable safety and favorable activity of glofitamab for refractory, aggressive B-cell non-Hodgkin lymphoma, with frequent and durable CRs.
